- Home
- ALXO vs MIRA Comparison
ALXO vs MIRA Comparison
Compare ALXO & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- MIRA
- Stock Information
- Founded
- ALXO 2015
- MIRA 2020
- Country
- ALXO United States
- MIRA United States
- Employees
- ALXO N/A
- MIRA N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- MIRA Biotechnology: Pharmaceutical Preparations
- Sector
- ALXO Health Care
- MIRA Health Care
- Exchange
- ALXO Nasdaq
- MIRA Nasdaq
- Market Cap
- ALXO 24.0M
- MIRA 19.5M
- IPO Year
- ALXO 2020
- MIRA 2023
- Fundamental
- Price
- ALXO $1.17
- MIRA $1.43
- Analyst Decision
- ALXO Strong Buy
- MIRA Strong Buy
- Analyst Count
- ALXO 6
- MIRA 1
- Target Price
- ALXO $3.30
- MIRA $17.00
- AVG Volume (30 Days)
- ALXO 1.7M
- MIRA 312.4K
- Earning Date
- ALXO 08-12-2025
- MIRA 08-14-2025
- Dividend Yield
- ALXO N/A
- MIRA N/A
- EPS Growth
- ALXO N/A
- MIRA N/A
- EPS
- ALXO N/A
- MIRA N/A
- Revenue
- ALXO N/A
- MIRA N/A
- Revenue This Year
- ALXO N/A
- MIRA N/A
- Revenue Next Year
- ALXO N/A
- MIRA N/A
- P/E Ratio
- ALXO N/A
- MIRA N/A
- Revenue Growth
- ALXO N/A
- MIRA N/A
- 52 Week Low
- ALXO $0.40
- MIRA $0.73
- 52 Week High
- ALXO $2.59
- MIRA $2.70
- Technical
- Relative Strength Index (RSI)
- ALXO 75.79
- MIRA 45.66
- Support Level
- ALXO $0.80
- MIRA $1.36
- Resistance Level
- ALXO $1.04
- MIRA $1.56
- Average True Range (ATR)
- ALXO 0.11
- MIRA 0.08
- MACD
- ALXO 0.05
- MIRA -0.02
- Stochastic Oscillator
- ALXO 96.85
- MIRA 36.36
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.